HyperQure™ Demonstrates Strong BP Reduction in Initial Clinical Cases from Korea – Published in JACC: Case Reports

DeepQure announced that initial clinical case results from South Korea using its novel HyperQure™ laparoscopic renal denervation (RDN) system have been published in JACC: Case Reports, an official journal of the American College of Cardiology (ACC).

The article presents the first two patients treated in Korea as part of an ongoing clinical study for resistant hypertension, and highlights significant reductions in blood pressure with no adverse events observed during the 3-month follow-up period.

In the two cases, 24-hour systolic blood pressure dropped from 140 mmHg to 104 mmHg and from 199 mmHg to 104 mmHg, representing reductions of 36 mmHg and 95 mmHg, respectively. These improvements were achieved even after reducing the number of antihypertensive medications by three and four, respectively—demonstrating both strong efficacy and potential for medication tapering.

DeepQure noted that these results compare favorably with data from FDA-approved intravascular RDN systems, such as Medtronic’s Symplicity Spyral and Recor Medical’s Paradise. Early clinical studies of those devices reported average systolic reductions of only 5.4 mmHg and 8.5 mmHg, respectively, over a similar period.

HyperQure™ was developed over nearly a decade under the leadership of Professor Chang-Wook Jeong at Seoul National University Hospital. Unlike conventional intravascular RDN, HyperQure™ uses a laparoscopic extravascular approach, enabling more complete nerve targeting and access to anatomically complex renal arteries.

DeepQure is currently conducting clinical trials of HyperQure™ in both South Korea and the United States. The Korean study is in its final stages, while the U.S. trial is ongoing at five leading academic centers.

“We believe this early clinical data highlights HyperQure’s potential to set a new standard in RDN therapy,” said a DeepQure spokesperson. “With strong quantitative results from Korea and the U.S., we are accelerating our path toward global market entry.”

(Source: edaily)